B. Metzler seel. Sohn & Co. AG Has $711,000 Stake in Solventum Corporation $SOLV

Key Points

• B. Metzler seel. Sohn & Co. AG cut its stake in Solventum by 68.6% in Q4, leaving 8,972 shares worth $711,000 after selling 19,561 shares.
• Director Amy McBride Wendell purchased 1,475 shares at an average price of $68.03 (≈$100,344), increasing her holding to 5,039 shares—a 41.39% rise in her position.
• Solventum beat Q4 estimates with $1.57 EPS (vs. $1.50) and $2.0B revenue (vs. $1.96B), set FY2026 guidance of $6.40–$6.60 EPS, and carries a consensus analyst rating of Hold with a $90.09 target.

B. Metzler seel. Sohn & Co. AG cut its stake in shares of Solventum Corporation (NYSE:SOLV - Free Report) by 68.6% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 8,972 shares of the company's stock after selling 19,561 shares during the quarter. B. Metzler seel. Sohn & Co. AG's holdings in Solventum were worth $711,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Hilltop National Bank lifted its holdings in Solventum by 71.3% during the 4th quarter. Hilltop National Bank now owns 310 shares of the company's stock worth $25,000 after buying an additional 129 shares during the period. Measured Wealth Private Client Group LLC acquired a new position in Solventum during the 3rd quarter worth about $25,000. JNBA Financial Advisors lifted its holdings in Solventum by 205.4% during the 4th quarter. JNBA Financial Advisors now owns 339 shares of the company's stock worth $27,000 after buying an additional 228 shares during the period. CYBER HORNET ETFs LLC acquired a new position in Solventum during the 2nd quarter worth about $28,000. Finally, Deseret Mutual Benefit Administrators lifted its holdings in Solventum by 78.7% during the 3rd quarter. Deseret Mutual Benefit Administrators now owns 370 shares of the company's stock worth $27,000 after buying an additional 163 shares during the period.

Insider Buying and Selling at Solventum

In other Solventum news, Director Amy Mcbride Wendell acquired 1,475 shares of the stock in a transaction dated Tuesday, March 10th. The stock was purchased at an average cost of $68.03 per share, with a total value of $100,344.25. Following the transaction, the director owned 5,039 shares in the company, valued at approximately $342,803.17. The trade was a 41.39% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink. Company insiders own 0.24% of the company's stock.

Solventum Stock Performance

SOLV stock opened at $68.55 on Monday. The stock has a 50-day moving average price of $68.52 and a 200-day moving average price of $74.62. Solventum Corporation has a 1-year low of $62.38 and a 1-year high of $88.20. The company has a current ratio of 1.23, a quick ratio of 0.89 and a debt-to-equity ratio of 1.00. The firm has a market cap of $11.89 billion, a PE ratio of 7.73, a price-to-earnings-growth ratio of 1.12 and a beta of 0.71.

Solventum (NYSE:SOLV - Get Free Report) last posted its quarterly earnings data on Thursday, February 26th. The company reported $1.57 earnings per share for the quarter, topping the consensus estimate of $1.50 by $0.07. Solventum had a return on equity of 25.26% and a net margin of 18.69%.The firm had revenue of $2 billion during the quarter, compared to analyst estimates of $1.96 billion. During the same period last year, the company posted $1.41 EPS. The business's quarterly revenue was down 3.7% on a year-over-year basis. Solventum has set its FY 2026 guidance at 6.400-6.600 EPS. As a group, equities research analysts expect that Solventum Corporation will post 6.5 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research analysts have commented on SOLV shares. Wells Fargo & Company raised Solventum to a "hold" rating in a report on Wednesday, March 18th. Weiss Ratings reaffirmed a "hold (c)" rating on shares of Solventum in a report on Tuesday, January 27th. Stifel Nicolaus lifted their target price on Solventum from $88.00 to $105.00 and gave the stock a "buy" rating in a report on Wednesday, January 7th. Rothschild & Co Redburn started coverage on Solventum in a report on Tuesday, March 24th. They set a "sell" rating and a $60.00 target price on the stock. Finally, Piper Sandler cut their target price on Solventum from $98.00 to $92.00 and set an "overweight" rating on the stock in a report on Friday, April 17th. Seven investment analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, Solventum has an average rating of "Hold" and a consensus target price of $90.09.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.

Want to see what other hedge funds are holding SOLV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Solventum Corporation (NYSE:SOLV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.